NAFT-500
Phase 3Small molecule
NAFT-500 is one of 20 small molecule programs targeting Tinea Pedis. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Tinea Pedis
#DrugCompanyPhaseTrials
1Lotrimin
BayerApproved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lamisil
NovartisPhase 3
Nizoral
WWim Janssens
Phase 3
Luzu
BBausch Health Americas, Inc.
Approved
Inomax
MMallinckrodt
Phase 2
Ciclopirox Olamine
AAtlas Molecular Pharma
Phase 3
Terbinafine Hydrochloride
NovartisPhase 2
NAFT-500
MMerz North America, Inc.
Phase 3
VT-1161
VViamet
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NAFT-500. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMerz North America, Inc.